↑ Read the latest from the desks · fresh intelligence, published daily✦Quiet reading✦No ads, ever✦Ad-free articles read by humans today …↑✦Boards engagement today … people · … AI✦Corporate brand & media services✦Made in Virginia Beach since 1997✦
Seaport Therapeutics$SPTX · filed: 🫧 Edgar looked up Seaport TherapeuticsCheck ▾Close ▴
What Seaport Therapeutics filed
🫧 Edgar looked up Seaport Therapeutics, Inc. ($SPTX). Last filing: 10-Q, 2026-11-02. 4 event filings (8-K) in the past twelve months. Every figure links to the filing it came from on Seaport Therapeutics’s card.
Figures as filed with the SEC. Ranges, scores and boats are statistical descriptions of past filings, not ratings or recommendations. Reporting, not advice.
In plain words
First neuropsych IPO since November tests whether pre-revenue CNS plays can access public capital after Sage's stumble compressed sector multiples **67%**.
$201 million
initial public offering scheduled to close this week
$225 million
in Series B funding led by Deerfield Management in…
18-22% dilution
based on typical biotech IPO structures
$250 million
offering in February 2024 and subsequently traded down
Seaport Therapeutics filed pricing terms for a $201 million initial public offering scheduled to close this week, becoming the first neuropsychiatric biotech to test U.S. public markets since November. The Boston-based company develops central nervous system therapies and holds no marketed products. Renaissance Capital flagged the pricing notice Tuesday morning.
Seaport's pipeline centers on STP-6073, a Phase 2 candidate targeting major depressive disorder, and STP-2101, a preclinical GABA modulator for epilepsy. The company last raised $225 million in Series B funding led by Deerfield Management in October 2023, pricing that round at an undisclosed pre-money valuation. Underwriters include J.P. Morgan, Leerink Partners, and TD Cowen. The offering represents roughly 18-22% dilution based on typical biotech IPO structures, though exact share count remains unconfirmed.
This marks the earliest calendar neuropsychiatric IPO since Neumora Therapeutics priced a $250 million offering in February 2024 and subsequently traded down 41% through year-end. Psychiatric drug developers face compressed multiples after Sage Therapeutics' $1.5 billion zuranolone launch underperformed consensus by 67% in its first four quarters, and Axsome Therapeutics trades at 4.2x forward sales despite approval momentum. Allocators pulled $890 million from biotech-focused mutual funds in December alone, per Morningstar flows. Seaport's willingness to price into this environment suggests either pricing discipline or investor fatigue with private rounds.
The neuropsych category itself remains fractured. While Karuna Therapeutics commanded a $14 billion Bristol Myers Squibb acquisition in December 2023, that deal capitalized on a late-stage schizophrenia asset with visible Phase 3 data. Seaport's STP-6073 completed a 180-patient Phase 2 trial in November, posting topline results the company called statistically significant but not yet peer-reviewed. The delta between Karuna's exit multiple and current public comps suggests investors now separate late-stage psychiatric stories from earlier bets. Seaport's timing places it in the latter.
Watch whether the deal prices at or below the midpoint of its undisclosed range, typically a 15-18% discount signal. If Seaport opens below issue price on day one, expect two follow-on neuropsych IPOs currently in SEC registration—names unconfirmed but rumored to include a Boston anxiety-disorder play—to delay into March at minimum. Conversely, a clean tape through Friday strengthens the case for $1.2-1.8 billion in biotech IPO volume before the end of Q1, matching 2024's anemic first-quarter pace.
The company's underwriters collected $47 million in fees across the last eight CNS IPOs, five of which now trade beneath issue. Seaport's test is whether $201 million in primary capital justifies public-market risk when private neuro-focused crossover funds still hold $3.1 billion in dry powder.
Branded by POPS4 · proof in 60 seconds
For the principal
If Seaport opens flat or up, neuropsych private books reprice upward 8-12%; if down, delay neuro exits six months.
For the operator
Track day-one close versus issue; sub-issue print kills two queued neuropsych S-1s and confirms compressed CNS multiples persist through Q1.
For the house
Huang Goodman holds no SPTX allocation; monitoring for crossover signal if pricing comes 12%+ below rumored private marks.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.